MoonLake Immunotherapeutics Faces Class Action Lawsuit After Critical Phase 3 Trial Data

MoonLake Immunotherapeutics Faces Potential Class Action

MoonLake Immunotherapeutics (NASDAQ: MLTX) is currently under legal scrutiny as a global plaintiffs' rights law firm, Hagens Berman, reminds investors of the impending class action deadline. Investors in MoonLake must act by December 15, 2025, to potentially become lead plaintiffs in a case centered on the disappointing results of the company's Phase 3 clinical trials.

Legal Context and Background

Following the release of disheartening data from its sole drug candidate, SLK, a significant drop in stock price is reported. From a solid $61.99 in market value, shares plummeted to $6.24, representing an alarming decline of approximately 90% within a matter of weeks.

Reed Kathrein, a partner at Hagens Berman, emphasizes the importance of this lawsuit for shareholders who may have been kept in the dark regarding the truth of SLK's clinical performance. The crux of the legal contention lies in whether MoonLake's public statements accurately mirrored the negative reality encountered in their clinical data.

The Allegations

Misrepresentation of Data

The key accusation against MoonLake is the alleged concealment of unfavorable facts regarding SLK’s efficacy and how it stands against competitors like BIMZELX, a well-known monoclonal antibody. Investigators at Hagens Berman are delving into claims that the company misrepresented the clinical benefits purportedly conferred by SLK’s unique Nanobody structure.

They are scrutinizing whether the anticipation of superior clinical outcomes over traditional monoclonal antibodies was unjustified and whether the trial results from the VELA studies truly reflected its market potential.

Competitive Positioning

The litigation focuses on whether MoonLake adequately communicated the competitive landscape in which SLK operates. Notably, allegations arise that SLK shares the same molecular targets as BIMZELX, leading investors to question its unique therapeutic position.

Financial Implications

Investors who purchased shares of MoonLake between March 10, 2024, and September 29, 2025, may be eligible to join the class action. The dramatic stock drop raises queries about financial losses sustained during this period. Investors concerned about their financial accountability due to these alleged misrepresentations are being encouraged to contact Hagens Berman for guidance.

Next Steps

To address these concerns, potential lead plaintiffs are urged to act swiftly. Legal actions of this magnitude can take years to resolve, but those impacted have a small window to submit claims and discuss their experiences. Reed Kathrein and his team are committed to providing legal support and insight into how best to navigate this challenging situation.

Furthermore, whistleblowers with information regarding MoonLake's practices are also encouraged to consider their options under the SEC Whistleblower program, which offers rewards for valuable contributions to investigations.

Hagens Berman’s Track Record

Hagens Berman boasts a solid history of securing over $2.9 billion in settlements for investors in various similar lawsuits. Their focus lies in holding corporations accountable for negligence and maintaining transparency in business practices.

Conclusion

For investors in MoonLake Immunotherapeutics, the next few days are crucial. The deadline for action is just around the corner, and understanding the full ramifications of the Phase 3 trial outcomes could dictate the path forward for many investors. Hagens Berman is available to assist those affected, providing clarity and direction in the face of uncertainty.

For more information on how to participate in the class action lawsuit or to connect with legal representatives, interested parties are encouraged to reach out immediately.